Glythera Limited is a biotechnology company specializing in the development of next generation biotherapeutics through the application of our advanced proprietary linker and stable glycan technologies, PermaLink™ and PermaCarb™.
Based in the North East of the UK, our capabilities extend beyond the development of our proprietary technologies. From our dedicated bioprocessing and chemistry laboratories, we work closely with our partners to progress applications of the PermaLink™ and PermaCarb™ technologies.
Our core technologies allow the selective and stable functionalization and glycosylation of biopharmaceuticals for improved stability, bioavailability and efficacy in oncology and therapeutics applications.
We are open to opportunities for technology out-licensing, collaboration or provision of full service business models for the use of PermaLink™ or PermaCarb™.
If you are looking to improve control, efficiency and post-transitional modification in the development of protein conjugates and biotherapeutics then our dedicated team would be happy to discuss the opportunities with you.
Herschel Annex, King's Road, Newcastle-upon-Tyne
NE1 7RU, UK.